NephroGenex Company Profile (NASDAQ:NRX)

About NephroGenex (NASDAQ:NRX)

NephroGenex logoNephroGenex, Inc. is a pharmaceutical company. The Company is focused on the development of therapeutics to treat kidney disease. The Company has paused the clinical program of its product candidate, oral Pyridorin, for the treatment of diabetic nephropathy. The Company was primarily focused on the Phase III Pyridorin program, and other planned clinical and nonclinical studies and other work needed to submit Pyridorin for acute kidney injury (AKI), as well as the treatment of diabetic nephropathy in patients with Type II diabetes for regulatory approval in the United States and Europe. The Company has not generated any revenues.

Industry, Sector and Symbol:
  • Sector: Healthcare
  • Industry: Drugs - Generic
  • Sub-Industry: N/A
  • Symbol: NASDAQ:NRX
  • CUSIP: N/A
  • Web: N/A
Average Prices:
  • 50 Day Moving Avg: $0.40
  • 200 Day Moving Avg: $1.17
  • 52 Week Range: $0.10 - $8.90
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: -0.08
  • P/E Growth: 0.0000
Misc:
  • Average Volume: 288,621 shs.
 

Frequently Asked Questions for NephroGenex (NASDAQ:NRX)

What is NephroGenex's stock symbol?

NephroGenex trades on the NASDAQ under the ticker symbol "NRX."

How were NephroGenex's earnings last quarter?

NephroGenex Inc (NASDAQ:NRX) issued its earnings results on Wednesday, November, 11th. The company reported ($0.53) EPS for the quarter, topping the Thomson Reuters' consensus estimate of ($0.65) by $0.12. View NephroGenex's Earnings History.

Where is NephroGenex's stock going? Where will NephroGenex's stock price be in 2017?

1 brokerages have issued 1-year price objectives for NephroGenex's stock. Their predictions range from $17.50 to $17.50. On average, they expect NephroGenex's share price to reach $17.50 in the next year. View Analyst Ratings for NephroGenex.

Who are some of NephroGenex's key competitors?

How do I buy NephroGenex stock?

Shares of NephroGenex can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of NephroGenex stock cost?

One share of NephroGenex stock can currently be purchased for approximately $0.14.

Analyst Ratings

Consensus Ratings for NephroGenex (NASDAQ:NRX) (?)
Ratings Breakdown: 1 Buy Rating
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $17.50 (12,391.08% upside)

Analysts' Ratings History for NephroGenex (NASDAQ:NRX)
Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
3/29/2017FBR & CoReiterated RatingOutperform$17.50LowView Rating Details
4/15/2016Rodman & RenshawReiterated RatingNeutralN/AView Rating Details
4/8/2016HC WainwrightDowngradeBuy -> NeutralN/AView Rating Details
8/17/2015MLV & Co.Reiterated RatingBuy$20.00N/AView Rating Details
(Data available from 5/26/2015 forward)

Earnings

Earnings History for NephroGenex (NASDAQ:NRX)
Earnings by Quarter for NephroGenex (NASDAQ:NRX)
Earnings History by Quarter for NephroGenex (NASDAQ:NRX)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/11/2015Q315($0.65)($0.53)ViewListenView Earnings Details
8/12/2015Q215($0.56)($0.72)ViewListenView Earnings Details
5/13/2015Q115($0.62)($0.58)ViewN/AView Earnings Details
3/24/2015Q414($0.58)($0.60)ViewN/AView Earnings Details
11/12/2014Q314($0.46)($0.50)ViewN/AView Earnings Details
8/11/2014($0.24)($0.61)ViewN/AView Earnings Details
5/14/2014Q114($0.37)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for NephroGenex (NASDAQ:NRX)
Current Year EPS Consensus Estimate: $-0.3000 EPS
Next Year EPS Consensus Estimate: $-1.7100 EPS

Dividends

Dividend History for NephroGenex (NASDAQ:NRX)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for NephroGenex (NASDAQ:NRX)
Insider Trades by Quarter for NephroGenex (NASDAQ:NRX)
Insider Trades by Quarter for NephroGenex (NASDAQ:NRX)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
1/6/2015Ventures V L.P. RhoMajor ShareholderSell273,860$10.58$2,897,438.80View SEC Filing  
11/25/2014Bob PetersonVPBuy2,000$4.20$8,400.00View SEC Filing  
2/14/2014Robert R SeltzerDirectorBuy790,000$12.00$9,480,000.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for NephroGenex (NASDAQ:NRX)
Latest Headlines for NephroGenex (NASDAQ:NRX)
Source:
DateHeadline
americanbankingnews.com logoNephroGenex (NRX) Getting Positive Media Coverage, Report Shows
www.americanbankingnews.com - April 27 at 5:22 PM
americanbankingnews.com logoNephroGenex (NRX) Getting Favorable Media Coverage, AlphaOne Reports
www.americanbankingnews.com - April 20 at 4:26 PM
finance.yahoo.com logoNaturex CEO Interview - FY 2016 Results (Video)
finance.yahoo.com - March 30 at 7:09 PM
americanbankingnews.com logoFBR & Co Reiterates "Outperform" Rating for NephroGenex Inc (NRX)
www.americanbankingnews.com - March 29 at 5:25 PM
feeds.benzinga.com logo3 Companies Filed For Chapter 11 Bankruptcy Today
feeds.benzinga.com - May 2 at 2:37 PM
finance.yahoo.com logoNephroGenex Files For Bankruptcy Protection Under Chapter 11
finance.yahoo.com - May 2 at 9:43 AM
bizjournals.com logoResearch Triangle area's biotech sector in steep bear market
www.bizjournals.com - April 26 at 3:00 PM
bizjournals.com logoHow NephroGenex went from darling to disaster
www.bizjournals.com - April 14 at 4:30 PM
finance.yahoo.com logoNephroGenex downgraded by H.C. Wainwright
finance.yahoo.com - April 8 at 7:10 AM
finance.yahoo.com logoNATUREX - FY 2015 Results
finance.yahoo.com - March 31 at 2:46 AM
biz.yahoo.com logoNEPHROGENEX, INC. Files SEC form 8-K, Termination of a Material Definitive Agreement, Costs Associated with Exit or D
biz.yahoo.com - February 24 at 4:31 PM
feeds.benzinga.com logoHere's Why NephroGenex Plunged 40% On Wednesday
feeds.benzinga.com - February 24 at 3:16 PM
bizjournals.com logoNephroGenex stock tumbles after announcement to halt trial over consideration of reverse merger
www.bizjournals.com - February 24 at 11:24 AM
finance.yahoo.com logoNephroGenex Provides Corporate Update
finance.yahoo.com - February 24 at 9:20 AM
biz.yahoo.com logoQ4 2015 NephroGenex Inc Earnings Release - After Market Close
biz.yahoo.com - February 24 at 7:07 AM
finance.yahoo.com logoNephroGenex to Host Conference Call and Webcast on Fourth Quarter and Full Year 2015 Financial Results on Thursday, February 25, 2016
finance.yahoo.com - February 16 at 8:00 AM
businesswire.com logoNephroGenex to Present at the 18th Annual BIO CEO & Investor Conference - Business Wire (press release)
www.businesswire.com - January 27 at 1:43 PM
nasdaq.com logoAMGN Gets FDA Nod, Data Awaits RGLS In Feb, FORWARD Puts ALKS On The Back Foot - Nasdaq
www.nasdaq.com - January 22 at 8:38 PM
streetinsider.com logoPre-Open Stock Movers 01/22: (NRX) (EGHT) (CHK) Higher; (CSII) (LGCY) (DGII) Lower (more...) - StreetInsider.com
www.streetinsider.com - January 22 at 8:38 PM
streetinsider.com logoNephroGenex (NRX) Reports IDSMB Recommendation to Continue Oral Pyridorin Phase 3 as Planned
www.streetinsider.com - January 22 at 8:38 PM
streetinsider.com logoNephroGenex (NRX) Reports IDSMB Recommendation to Continue Oral Pyridorin ... - StreetInsider.com
www.streetinsider.com - January 21 at 8:49 PM
finance.yahoo.com logo4:11 pm NephroGenex announces independent DSMB recommendation to continue Phase 3 study of oral Pyridorin in diabetic nephropathy without modification
finance.yahoo.com - January 21 at 4:11 PM
biz.yahoo.com logoNEPHROGENEX, INC. Files SEC form 8-K, Regulation FD Disclosure, Financial Statements and Exhibits
biz.yahoo.com - January 7 at 4:03 PM
finance.yahoo.com logoNephroGenex to Participate in Two Healthcare Conferences in January
finance.yahoo.com - January 6 at 8:00 AM
finance.yahoo.com logoNephroGenex Announces Formation of Scientific Advisory Board
finance.yahoo.com - January 5 at 8:00 AM
bizjournals.com logoRaleigh drug developer sees shares soar on good news from FDA
www.bizjournals.com - December 14 at 5:40 PM
finance.yahoo.com logoThanks, FDA: NephroGenex Investors Rejoice After New Clearance
finance.yahoo.com - December 14 at 12:52 PM
thestreet.com logoNephroGenex (NRX) Stock Soars After FDA Approves Clinical Trials for Kidney Treatment
www.thestreet.com - December 14 at 11:29 AM
finance.yahoo.com logoNephroGenex Announces FDA Clearance of IND Application for Clinical Study of Intravenous Pyridorin in the Treatment of Acute Kidney Injury
finance.yahoo.com - December 14 at 8:00 AM
finance.yahoo.com logoNEPHROGENEX, INC. Financials
finance.yahoo.com - December 8 at 1:18 PM
biz.yahoo.com logoNEPHROGENEX, INC. Files SEC form 8-K, Financial Statements and Exhibits
biz.yahoo.com - November 13 at 7:14 AM

Social

Chart

NephroGenex (NRX) Chart for Friday, May, 26, 2017

This page was last updated on 5/26/2017 by MarketBeat.com Staff